Overview

  • Product name
    Anti-RUNX1 / AML1 antibody
    See all RUNX1 / AML1 primary antibodies
  • Description
    Rabbit polyclonal to RUNX1 / AML1
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WB, ICC/IFmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
    Predicted to work with: Cow, Pig, Rhesus monkey
  • Immunogen

    Recombinant fragment within Human RUNX1/ AML1 (internal sequence). The exact sequence is proprietary.
    Database link: Q01196

  • Positive control
    • WB: RAW 264.7, C2C12, Rat2 and Jurkat whole cell extracts; Jurkat nuclear extract. ICC/IF: SK-N-SH cells.

Properties

Applications

Our Abpromise guarantee covers the use of ab229482 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/3000. Predicted molecular weight: 48 kDa.
ICC/IF 1/100 - 1/1000.

Target

  • Function
    CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits MYST4-dependent transcriptional activation.
  • Tissue specificity
    Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood.
  • Involvement in disease
    Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.
    Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.
    Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.
    Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.
    Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.
    Defects in RUNX1 are the cause of familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]. FPDMM is an autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia.
    Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.
    Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.
  • Sequence similarities
    Contains 1 Runt domain.
  • Domain
    A proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes.
  • Post-translational
    modifications
    Phosphorylated in its C-terminus upon IL-6 treatment. Phosphorylation enhances interaction with MYST3.
    Methylated.
  • Cellular localization
    Nucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • Acute myeloid leukemia 1 antibody
    • Acute myeloid leukemia 1 protein antibody
    • alpha subunit core binding factor antibody
    • AML 1 antibody
    • AML1 antibody
    • AML1 EVI 1 antibody
    • AML1 EVI 1 fusion protein antibody
    • Aml1 oncogene antibody
    • AMLCR 1 antibody
    • AMLCR1 antibody
    • CBF alpha 2 antibody
    • CBF-alpha-2 antibody
    • CBFA 2 antibody
    • CBFA2 antibody
    • Core binding factor alpha 2 subunit antibody
    • Core binding factor runt domain alpha subunit 2 antibody
    • Core-binding factor subunit alpha-2 antibody
    • EVI 1 antibody
    • EVI1 antibody
    • HGNC antibody
    • Oncogene AML 1 antibody
    • Oncogene AML-1 antibody
    • OTTHUMP00000108696 antibody
    • OTTHUMP00000108697 antibody
    • OTTHUMP00000108699 antibody
    • OTTHUMP00000108700 antibody
    • OTTHUMP00000108702 antibody
    • PEA2 alpha B antibody
    • PEA2-alpha B antibody
    • PEBP2 alpha B antibody
    • PEBP2-alpha B antibody
    • PEBP2A2 antibody
    • PEBP2aB antibody
    • Polyomavirus enhancer binding protein 2 alpha B subunit antibody
    • Polyomavirus enhancer-binding protein 2 alpha B subunit antibody
    • Run1 antibody
    • Runt related transcription factor 1 antibody
    • Runt-related transcription factor 1 antibody
    • RUNX 1 antibody
    • Runx1 antibody
    • RUNX1_HUMAN antibody
    • SL3 3 enhancer factor 1 alpha B subunit antibody
    • SL3-3 enhancer factor 1 alpha B subunit antibody
    • SL3/AKV core binding factor alpha B subunit antibody
    • SL3/AKV core-binding factor alpha B subunit antibody
    see all

Images

  • All lanes : Anti-RUNX1 / AML1 antibody (ab229482) at 1/1000 dilution

    Lane 1 : Jurkat (human T cell leukemia cell line from peripheral blood) whole cell extract
    Lane 2 : Jurkat nuclear extract

    Lysates/proteins at 30 µg per lane.

    Developed using the ECL technique.

    Predicted band size: 48 kDa



    10% SDS-PAGE

  • SK-N-SH (human neuroblastoma cell line) cells stained for RUNX1 / AML1 (green) using ab229482 at 1/400 dilution in ICC/IF. Cells were fixed in 4% paraformaldehyde at RT for 15 minutes.

    Nuclear counterstain: Hoechst 33342 (blue). The cytoskeleton is stained with Phalloidin (red).

  • All lanes : Anti-RUNX1 / AML1 antibody (ab229482) at 1/1000 dilution

    Lane 1 : RAW 264.7 (mouse macrophage cell line transformed with Abelson murine leukemia virus) whole cell extract
    Lane 2 : C2C12 (mouse myoblast cell line) whole cell extract

    Lysates/proteins at 30 µg per lane.

    Developed using the ECL technique.

    Predicted band size: 48 kDa



    10% SDS-PAGE

  • Anti-RUNX1 / AML1 antibody (ab229482) at 1/1000 dilution + Rat2 (rat fibroblast cell line) whole cell extract at 30 µg

    Developed using the ECL technique.

    Predicted band size: 48 kDa



    10% SDS-PAGE

References

ab229482 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab229482.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up